The United States Food and Drug Administration (FDA) has approved the first daily oral pill for weight management, marking a major breakthrough in the treatment of obesity and overweight in adults. The medication, developed by pharmaceutical company Novo Nordisk, contains 25 mg of semaglutide and works by mimicking a natural hormone that reduces appetite and increases the feeling of fullness.
Clinical trials showed that participants who took the pill once a day achieved an average body weight reduction of more than 16%, a result comparable to existing injectable treatments for obesity.
The new pill is expected to be available in U.S. pharmacies starting in January 2026, potentially expanding access to weight-loss treatments, especially for people who prefer not to use injections or are looking for a more convenient option.
Why is this approval so important for public health?
Because obesity affects nearly 100 million Americans, and an effective oral option could improve access to treatment, increase adherence, and offer a less invasive alternative for millions seeking to lose weight.
